|
Impact of prior anticancer treatments on palbociclib (PAL) clinical outcomes in patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2−) advanced breast cancer (ABC) in real-world settings. |
| |
|
Consulting or Advisory Role - Gilead Sciences; Pfizer |
Research Funding - Armada (Inst); Daiichi Sankyo/Astra Zeneca; Genentech; Pfizer |
Travel, Accommodations, Expenses - Gilead Sciences |
| |
|
Honoraria - Pfizer; Tempus |
Consulting or Advisory Role - Pfizer; TD2; Tempus |
Speakers' Bureau - Pfizer; Tempus |
Travel, Accommodations, Expenses - Pfizer |
| |
|
Consulting or Advisory Role - AstraZeneca; BeiGene; Janssen |
| |
|
Consulting or Advisory Role - AstraZeneca; AstraZeneca; Carrick Therapeutics; Daiichi Sankyo/Astra Zeneca; DualityBio; Gilead Sciences; Jazz Pharmaceuticals; Kestrel Therapeutics; Merck; Novartis; Pfizer; Scorpion Therapeutics; Seagen; Sermonix Pharmaceuticals; Stemline Therapeutics |
Speakers' Bureau - AstraZeneca; Gilead Sciences; SeaGen; Stemline Therapeutics |
Research Funding - Arvinas; AstraZeneca/Daiichi Sankyo (Inst); Dantari (Inst); G1 Therapeutics (Inst); H3 Biomedicine (Inst); HiberCell (Inst); Novartis; Novartis; Olema Pharmaceuticals (Inst); Orinove (Inst); Pfizer (Inst); Sanofi (Inst); Scorpion Therapeutics; Seagen (Inst); Zymeworks (Inst) |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
Employment - Novant Health Cancer Institute |
| |
|
|
Stock and Other Ownership Interests - Pfizer |
| |
|
Employment - ICON Clinical Research |
Research Funding - Pfizer (Inst) |
| |
|
|
Stock and Other Ownership Interests - Pfizer |
| |
|
|
Stock and Other Ownership Interests - Pfizer |
Travel, Accommodations, Expenses - Pfizer |
| |
|
Consulting or Advisory Role - Ambrx; AstraZeneca; Genomic Health; Gilead Sciences; GlaxoSmithKline; Menarini; Novartis; OncoPep; Personalis; Pfizer; Roche; Sermonix Pharmaceuticals |
Research Funding - Ambrx (Inst); Novartis (Inst); Pfizer (Inst); Polyphor (Inst) |
Travel, Accommodations, Expenses - AstraZeneca; Novartis |